Fluorescence detection of MMP-9. I. MMP-9 selectively cleaves Lys-Gly- Pro-Arg-Ser-Leu-Ser-Gly-Lys Peptide

Current Pharmaceutical Biotechnology

Volumn 12, Issue 5, 2011, Pages 834-838

  Fudala, Rafal ^a,b   Ranjan, Amalendu P ^c   Mukerjee, Anindita ^c   Vishwanatha, Jamboor K ^c   Gryczynski, Zygmunt ^a,d   Borejdo, Julian ^a   Sarkar, Pabak ^a   Gryczynski, Ignacy ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b JAN KOCHANOWSKI UNIVERSITY   (Poland)

^c UNTHSC   (United States)

^d TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

Fluorescence; FRET; Labeled peptide; MMP 9

Indexed keywords

FLUORESCEIN; FLUORESCENT DYE; GELATINASE B; POLYPEPTIDE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; FLUORESCENCE ANALYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL;

EID: 79955612868     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795470967     Document Type: Article

References (22)

1. Didenko, V. V. DNA probes using fluorescence resonance energy transfer (FRET): designs and applications. Biotechniques, 2001, 31, 1106-1116.
2. Orpana, A. K. Fluorescence resonance energy transfer (FRET) using ssDNA binding fluorescent dye. Biomol. Eng., 2004, 21, 45-50.
3. Tan, W.; Wang, K.; Drake, T. J. Molecular beacons. Curr. Opin. Chem. Biol., 2004, 8, 547-553.
4. Schäferling, M.; Nagl, S. Optical technologies for the read out and quality control of DNA and protein microarrays. Anal. Bioanal. Chem., 2006, 385, 500-517.
5. Kridel, S. J.; Chen, E.; Kotra, L. P.; Howard, E. W.; Mobasher,. S.; Smith, J. W. Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem., 2001, 276, 20572-20578.
6. DeClerck, Y. A.; Yean, T. D.; Ratzkin, B. J. Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine endothelial cells. J. Biol. Chem., 1989, 264, 17445-17453.
7. Stetler-Stevenson, W. G.; Krutzsch, H. C.; Liotta L. A. A new member of the metalloproteinase inhibitor family. J. Biol. Chem., 1989, 264, 17374-17378.
8. Williamsen, R. A.; Marston, F.; Angel, S.; Koklitis, P.; Panico, M.; Morris, H. R.; Carne, A. F.; Smith, B. J.; Harris, T.; Freedman, R. B. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem. J., 1990, 268, 267-274.
9. Nagase, H.; Woessner, J. F. Matrix metalloproteinases. J. Biol. Chem., 1999, 274, 21491-21494.
10. Shapiro, S. D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 1998, 10, 602-608.
11. Westermarck, J.; Kähäri, V-M. Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J., 1999, 13, 781-792.
12. Liu, Z.; Zhou, X.; Shapiro, S.D.; Shipley, J. M.; Twining, S. S.; Diaz, L. A.; Senior, R. M.; Werb, Z. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell, 2000, 102(5), 647-655.
13. Lochter, A.; Sternligcht, M. D.; Werb, Z.; Bissel, M. J. The significance of matrix metalloproteinases during early stages of tumor progression. Ann. N. Y. Acad. Sci., 1998, 857, 180-193.
14. Stöcker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Rüth, F. X.; McKay, D. B.; Bode, W. The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci., 1995, 4(5), 823-840.
15. Bode, W.; Fernandez-Catalan, C.; Tschesche, H.; Grams, F.; Nagase, H.; Maskos. K. Structural properties of matrix metalloproteinases. Cell. Mol. Life. Sci., 1999, 55(4), 639-652.
16. Sternligcht, M. D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Ann. Rev. Cell Dev., Biol., 2001, 17, 463-516.
17. Garbisa, S.; Scagliotti, G.; Masiero, L.; Di Francesco, C.; Caenazzo, C.; Onisto, M.; Micela, M.; Stetler-Stevenson, W. G.; Liotta, L. A. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res., 1992, 52, 4548-4549.
18. Nakajima, M.; Welch, D. R.; Wynn, D. M.; Tsuruo, T.; Nicolson, G. L. Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res., 1993, 53, 5802-5807.
19. Gohji, K.; Fujimoto, N.; Komiyama, T.; Fujii, A.; Ohkawa, J.; Kamidono, S.; Nakajima, M. Elevation of serum levels of matrix metalloproteinase-2 and-3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer, 1996, 78, 2379-2387.
20. Guan, K. P.; Ye, H. Y.; Yan, Z.; Wang, Y.; Hou, S. K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology, 2003, 61, 719-723.
21. Vasala, K.; Turpeenniemi-Hujanen, T. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin. Biochem., 2007, 40, 640-644.
22. Wu, Z. S.; Wu, Q.; Yang, J. H.; Wang, H. Q.; Ding, X. D.; Yang, F.; Xu, X. C. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer, 2008, 122, 2050-2056.